{"nctId":"NCT00423657","briefTitle":"Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections","startDateStruct":{"date":"2007-03"},"conditions":["Bacterial Infections"],"count":680,"armGroups":[{"label":"Ceftaroline fosamil for Injection","type":"EXPERIMENTAL","interventionNames":["Drug: ceftaroline","Drug: Placebo"]},{"label":"IV Vancomycin plus IV Aztreonam","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: vancomycin plus aztreonam"]}],"interventions":[{"name":"ceftaroline","otherNames":["Experimental"]},{"name":"vancomycin plus aztreonam","otherNames":["Active Comparator"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.\n\nExclusion Criteria:\n\n* Prior treatment of current complicated skin and skin structure infection (cSSSI) with an antimicrobial.\n* Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Cure Rate at Test of Cure (TOC) (MITT Population)","description":"Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary.\n\nFailure: Requirement of alternative antimicrobial therapy for primary infection of complicated skin and skin structure infection (cSSSI) due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI.\n\nIndeterminate: Inability to determine an outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"291","spread":null},{"groupId":"OG001","value":"289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"PRIMARY","title":"The Primary Efficacy Outcome Measure Was the Per-subject Clinical Cure Rate at the TOC Visit in the Clinically Evaluable (CE) Populations.","description":null,"classes":[]},{"type":"SECONDARY","title":"To Evaluate the Microbiological Success Rate at the TOC Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"To Evaluate the Clinical Response at the End of Therapy (EOT) Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"To Evaluate the Clinical and Microbiological Response by Pathogen at the TOC Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"To Evaluate Clinical Relapse at the Late Follow Up (LFU) Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"To Evaluate Microbiological Reinfection or Recurrence at the LFU Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"To Evaluate Safety","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":341},"commonTop":["Pruritus","Nausea","Diarrhea","Headache","Rash"]}}}